ERBB2 and breast cancer: In this study, we compared three modalities—conventional microscopy, digital pathology, and an AI model—for the assessment of HER2 status and changes in HER2 expression in core biopsies, surgical specimens, and metastasis biopsies from 47 patients with advanced BC.